NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer

Author(s): Marco A. Calzado, Susanne Bacher, M. Lienhard Schmitz

Journal Name: Current Medicinal Chemistry

Volume 14 , Issue 3 , 2007

Become EABM
Become Reviewer
Call for Editor


The NF-κB/Rel signaling system is a paradigm for gene activation in response to inflammatory and menacing stimuli. Given the growing body of evidence showing an important involvement of NF-κB for the onset of autoimmune diseases and different types of cancer, NF-κB is an important drug target for the adjuvant therapy of these diseases. Great efforts have been made for the development of highly specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials. Here we discuss recent progress in the identification of druggable components of the NF- κB signaling system and the development and potential use of novel NF-κB inhibitors.

Keywords: Inflammation, cancer, NF-κB, Inhibitor, IκB, IKK, Transcription factor

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [367 - 376]
Pages: 10
DOI: 10.2174/092986707779941113
Price: $65

Article Metrics

PDF: 39